Tenderwize
Zurück zur Suche

Open house discount agreements for the active ingredient Umeclidinium bromide, ATC R03BB07

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Apr 30, 2027 · 248 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Umeclidiniumbromid, ATC R03BB07

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

25 / 100

Risikofaktoren

No minimum volume or revenue guarantee; the contract is non-exclusive and can be terminated or replaced by exclusive co...

The buyer reserves the right to replace open house agreements with exclusive discount contracts, leading to automatic t...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Entering into non-exclusive discount agreements for the active ingredient Umeclidinium bromide (ATC R03BB07) with pharmaceutical companies.
  • Agreements cover the supply of authorized and marketable drugs in Germany.
Vollständige Zusammenfassung anzeigen

Non-exclusive open house discount agreements for the active ingredient Umeclidinium bromide (ATC R03BB07) in Germany, offered by AOK Rheinland-Pfalz/Saarland. The model allows any pharmaceutical company to join at any time during the 24-month period from 01.07.2025 to 30.06.2027, with uniform terms and no competitive selection. The agreements may be replaced by exclusive discount contracts during the term.

Risiken

No minimum volume or revenue guarantee; the contract is non-exclusive and can be terminated or replaced by exclusive co...

The buyer reserves the right to replace open house agreements with exclusive discount contracts, leading to automatic t...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Drugs must be authorized and marketable in Germany (proof via Lauer-Taxe or AMIce database).

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of signed contract documents: either handwritten in duplicate or electronically with a qualified electronic signature (QES).

Zuschlagskriterien

Lot 1

No award criteria; open house model with automatic acceptance.

Auftraggeber

Lose (1)

LOT-0001

Open house discount agreements for the active ingredient Umeclidinium bromide, ATC R03BB07

Non-exclusive discount agreements for Umeclidinium bromide drugs, open to all pharmaceutical companies. Contracts have a maximum duration of 24 months, starting at the beginning of any month. The first possible start date is 01.07.2025. The agreements can be terminated with 6 weeks' notice and replaced by exclusive discount agreements.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Jun 2025 - Jun 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

No award criteria; open house model with automatic acceptance.

Frist

Deadline Apr 30, 2027

Vergabedetails

Veröffentlichungsdatum
18 May 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
319668-2025

Dokumente (1)

Ähnliche Ausschreibungen